Literature DB >> 24907359

SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms.

Emiliano Fabiani1, Giulia Falconi2, Luana Fianchi2, Marianna Criscuolo2, Giuseppe Leone2, Maria Teresa Voso2.   

Abstract

Entities:  

Keywords:  SETBP1 mutations; therapy-related myeloid neoplasms

Mesh：

Substances：

Year:  2014        PMID： 24907359      PMCID： PMC4562546          DOI： 10.3324/haematol.2014.108159

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  10 in total

1.  Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression.

Authors:  Hsin-An Hou; Yuan-Yeh Kuo; Jih-Luh Tang; Wen-Chien Chou; Ming Yao; Yan-Jun Lai; Chien-Chin Lin; Chien-Yuan Chen; Chieh-Yu Liu; Mei-Hsuan Tseng; Chi-Fei Huang; Ying-Chieh Chiang; Fen-Yu Lee; Ming-Chih Liu; Chia-Wen Liu; Shang-Yi Huang; Bor-Sheng Ko; Shang-Ju Wu; Woei Tsay; Yao-Chang Chen; Hwei-Fang Tien
Journal:  Am J Hematol       Date:  2013-11-20       Impact factor: 10.047

2.  Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases.

Authors:  M T Voso; E Fabiani; L Fianchi; G Falconi; M Criscuolo; R Santangelo; P Chiusolo; S Betti; F D'Alo'; S Hohaus; V De Stefano; G Leone
Journal:  Leukemia       Date:  2012-09-11       Impact factor: 11.528

3.  SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias.

Authors:  F Damm; R Itzykson; O Kosmider; N Droin; A Renneville; V Chesnais; V Gelsi-Boyer; S de Botton; N Vey; C Preudhomme; A Clavert; E Delabesse; S Park; D Birnbaum; M Fontenay; O A Bernard; E Solary
Journal:  Leukemia       Date:  2013-02-05       Impact factor: 11.528

4.  SETBP1 mutation analysis in 944 patients with MDS and AML.

Authors:  F Thol; K J Suchanek; C Koenecke; M Stadler; U Platzbecker; C Thiede; T Schroeder; G Kobbe; S Kade; P Löffeld; S Banihosseini; G Bug; O Ottmann; W-K Hofmann; J Krauter; N Kröger; A Ganser; M Heuser
Journal:  Leukemia       Date:  2013-05-07       Impact factor: 11.528

5.  Mutations in SETBP1 are recurrent in myelodysplastic syndromes and often coexist with cytogenetic markers associated with disease progression.

Authors:  Marta Fernandez-Mercado; Andrea Pellagatti; Cristina Di Genua; Maria Jose Larrayoz; Nils Winkelmann; Paula Aranaz; Adam Burns; Anna Schuh; Maria Jose Calasanz; Nicholas C P Cross; Jacqueline Boultwood
Journal:  Br J Haematol       Date:  2013-07-24       Impact factor: 6.998

6.  Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.

Authors:  Rocco Piazza; Simona Valletta; Nils Winkelmann; Sara Redaelli; Roberta Spinelli; Alessandra Pirola; Laura Antolini; Luca Mologni; Carla Donadoni; Elli Papaemmanuil; Susanne Schnittger; Dong-Wook Kim; Jacqueline Boultwood; Fabio Rossi; Giuseppe Gaipa; Greta P De Martini; Paola Francia di Celle; Hyun Gyung Jang; Valeria Fantin; Graham R Bignell; Vera Magistroni; Torsten Haferlach; Enrico Maria Pogliani; Peter J Campbell; Andrew J Chase; William J Tapper; Nicholas C P Cross; Carlo Gambacorti-Passerini
Journal:  Nat Genet       Date:  2012-12-09       Impact factor: 38.330

7.  Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia.

Authors:  Alan H Shih; Stephen S Chung; Emily K Dolezal; Su-Jiang Zhang; Omar I Abdel-Wahab; Christopher Y Park; Stephen D Nimer; Ross L Levine; Virginia M Klimek
Journal:  Haematologica       Date:  2013-01-24       Impact factor: 9.941

8.  A syndrome of severe midface retraction, multiple skull anomalies, clubfeet, and cardiac and renal malformations in sibs.

Authors:  A Schinzel; A Giedion
Journal:  Am J Med Genet       Date:  1978

9.  Genetic pathways leading to therapy-related myeloid neoplasms.

Authors:  Angela Stoddart; Megan E McNerney; Elizabeth Bartom; Rachel Bergerson; David J Young; Zhijian Qian; Jianghong Wang; Anthony A Fernald; Elizabeth M Davis; Richard A Larson; Kevin P White; Michelle M Le Beau
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-05-16       Impact factor: 2.576

10.  Somatic SETBP1 mutations in myeloid malignancies.

Authors:  Hideki Makishima; Kenichi Yoshida; Nhu Nguyen; Bartlomiej Przychodzen; Masashi Sanada; Yusuke Okuno; Kwok Peng Ng; Kristbjorn O Gudmundsson; Bandana A Vishwakarma; Andres Jerez; Ines Gomez-Segui; Mariko Takahashi; Yuichi Shiraishi; Yasunobu Nagata; Kathryn Guinta; Hiraku Mori; Mikkael A Sekeres; Kenichi Chiba; Hiroko Tanaka; Hideki Muramatsu; Hirotoshi Sakaguchi; Ronald L Paquette; Michael A McDevitt; Seiji Kojima; Yogen Saunthararajah; Satoru Miyano; Lee-Yung Shih; Yang Du; Seishi Ogawa; Jaroslaw P Maciejewski
Journal:  Nat Genet       Date:  2013-07-07       Impact factor: 38.330
  10 in total
  10 in total

Review 1.  Somatic SETBP1 mutations in myeloid neoplasms.

Authors:  Hideki Makishima
Journal:  Int J Hematol       Date:  2017-04-26       Impact factor: 2.490

2.  Therapy-associated myelodysplastic syndrome with monosomy 7 arising in a Muir-Torre Syndrome patient carrying SETBP1 mutation.

Authors:  David Ullman; Erin Baumgartner; Nicholas Wnukowski; Gabe Koenig; Fady M Mikhail; Peter Pavlidakey; Deniz Peker
Journal:  Mol Clin Oncol       Date:  2017-12-08

3.  The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution.

Authors:  Hamish S Scott; Christopher N Hahn; Devendra K Hiwase; Deepak Singhal; Li Yan A Wee; Monika M Kutyna; Rakchha Chhetri; Joel Geoghegan; Andreas W Schreiber; Jinghua Feng; Paul P-S Wang; Milena Babic; Wendy T Parker; Smita Hiwase; Suzanne Edwards; Sarah Moore; Susan Branford; Teodora Kuzmanovic; Nimit Singhal; Raghu Gowda; Anna L Brown; Peer Arts; Luen B To; Peter G Bardy; Ian D Lewis; Richard J D'Andrea; Jaroslaw P Maciejewski
Journal:  Leukemia       Date:  2019-05-14       Impact factor: 11.528

4.  Higher expression levels of the HOXA9 gene, closely associated with MLL-PTD and EZH2 mutations, predict inferior outcome in acute myeloid leukemia.

Authors:  Li Gao; Junzhong Sun; Fang Liu; Hui Zhang; Yigai Ma
Journal:  Onco Targets Ther       Date:  2016-02-09       Impact factor: 4.147

5.  Overlapping SETBP1 gain-of-function mutations in Schinzel-Giedion syndrome and hematologic malignancies.

Authors:  Rocio Acuna-Hidalgo; Pelagia Deriziotis; Marloes Steehouwer; Christian Gilissen; Sarah A Graham; Sipko van Dam; Julie Hoover-Fong; Aida B Telegrafi; Anne Destree; Robert Smigiel; Lindsday A Lambie; Hülya Kayserili; Umut Altunoglu; Elisabetta Lapi; Maria Luisa Uzielli; Mariana Aracena; Banu G Nur; Ercan Mihci; Lilia M A Moreira; Viviane Borges Ferreira; Dafne D G Horovitz; Katia M da Rocha; Aleksandra Jezela-Stanek; Alice S Brooks; Heiko Reutter; Julie S Cohen; Ali Fatemi; Martin Smitka; Theresa A Grebe; Nataliya Di Donato; Charu Deshpande; Anthony Vandersteen; Charles Marques Lourenço; Andreas Dufke; Eva Rossier; Gwenaelle Andre; Alessandra Baumer; Careni Spencer; Julie McGaughran; Lude Franke; Joris A Veltman; Bert B A De Vries; Albert Schinzel; Simon E Fisher; Alexander Hoischen; Bregje W van Bon
Journal:  PLoS Genet       Date:  2017-03-27       Impact factor: 5.917

6.  Clonal evolution in therapy-related neoplasms.

Authors:  Emiliano Fabiani; Giulia Falconi; Luana Fianchi; Marianna Criscuolo; Tiziana Ottone; Laura Cicconi; Stefan Hohaus; Simona Sica; Massimiliano Postorino; Antonino Neri; Marta Lionetti; Giuseppe Leone; Francesco Lo-Coco; Maria Teresa Voso
Journal:  Oncotarget       Date:  2017-02-14

7.  SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub.

Authors:  Rocco Piazza; Vera Magistroni; Sara Redaelli; Mario Mauri; Luca Massimino; Alessandro Sessa; Marco Peronaci; Maciej Lalowski; Rabah Soliymani; Caterina Mezzatesta; Alessandra Pirola; Federica Banfi; Alicia Rubio; Delphine Rea; Fabio Stagno; Emilio Usala; Bruno Martino; Leonardo Campiotti; Michele Merli; Francesco Passamonti; Francesco Onida; Alessandro Morotti; Francesca Pavesi; Marco Bregni; Vania Broccoli; Marc Baumann; Carlo Gambacorti-Passerini
Journal:  Nat Commun       Date:  2018-06-06       Impact factor: 14.919

8.  Whole-genome sequencing combined RNA-sequencing analysis of patients with mutations in SET binding protein 1.

Authors:  Li Liu; Xiaoshu Feng; Sihan Liu; Yanqiu Zhou; Xiaojing Dong; Hong Yao; Bo Tan
Journal:  Front Neurosci       Date:  2022-09-07       Impact factor: 5.152

Review 9.  SETBP1 dysregulation in congenital disorders and myeloid neoplasms.

Authors:  Nicoletta Coccaro; Giuseppina Tota; Antonella Zagaria; Luisa Anelli; Giorgina Specchia; Francesco Albano
Journal:  Oncotarget       Date:  2017-04-19

10.  Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia.

Authors:  Diletta Fontana; Daniele Ramazzotti; Andrea Aroldi; Sara Redaelli; Vera Magistroni; Alessandra Pirola; Antonio Niro; Luca Massimino; Cristina Mastini; Virginia Brambilla; Silvia Bombelli; Silvia Bungaro; Alessandro Morotti; Delphine Rea; Fabio Stagno; Bruno Martino; Leonardo Campiotti; Giovanni Caocci; Emilio Usala; Michele Merli; Francesco Onida; Marco Bregni; Elena Maria Elli; Monica Fumagalli; Fabio Ciceri; Roberto A Perego; Fabio Pagni; Luca Mologni; Rocco Piazza; Carlo Gambacorti-Passerini
Journal:  Hemasphere       Date:  2020-11-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.